期刊
LEUKEMIA
卷 25, 期 2, 页码 254-258出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2010.275
关键词
Ikaros; IKZF1; minimal residual disease (MRD); pediatric acute lymphoblastic leukemia (ALL); prognostic value; relapse prediction
资金
- Dutch Cancer Society [KUN2009-4298, EMCR2006-3547, SNWLK 97-1567, SNWLK 2000-2268]
- Quality of Life Gala Foundation
Response to therapy as determined by minimal residual disease (MRD) is currently used for stratification in treatment protocols for pediatric acute lymphoblastic leukemia (ALL). However, the large MRD-based medium risk group (MRD-M; 50-60% of the patients) harbors many relapses. We analyzed MRD in 131 uniformly treated precursor-B-ALL patients and evaluated whether combined MRD and IKZF1 (Ikaros zinc finger-1) alteration status can improve risk stratification. We confirmed the strong prognostic significance of MRD classification, which was independent of IKZF1 alterations. Notably, 8 of the 11 relapsed cases in the large MRD-M group (n = 81; 62%) harbored an IKZF1 alteration. Integration of both MRD and IKZF1 status resulted in a favorable outcome group (n = 104; 5 relapses) and a poor outcome group (n = 27; 19 relapses), and showed a stronger prognostic value than each of the established risk factors alone (hazard ratio (95%CI): 24.98 (8.29-75.31)). Importantly, whereas MRD and IKZF1 status alone identified only 46 and 54% of the relapses, respectively, their integrated use allowed prediction of 79% of all the relapses with 93% specificity. Because of the unprecedented sensitivity in upfront relapse prediction, the combined parameters have high potential for future risk stratification, particularly for patients originally classified as non-high risk, such as the large group of MRD-M patients. Leukemia (2011) 25, 254-258; doi:10.1038/leu.2010.275; published online 19 November 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据